Pfizer Inc. Y BioNTech I KNOW They said Saturday that a booster dose of updated versions of their vaccine for the Covid-19modified specifically to combat the variant of the Omicron coronavirusgenerated a greater immune response against that variant.
Advisers to the US Food and Drug Administration are scheduled to meet Tuesday to discuss whether to update Covid-19 vaccines for the fall. According to experts, the updated injections are likely to be redesigned to combat Omicron variant.
Pfizer Y BioNTech They said that the 30- and 60-microgram doses of a vaccine aimed only at subvariant BA.1 Omicron that circulated last winter caused a 13.5- and 19.6-fold increase in neutralizing geometric titers against that subvariant.
A version of the vaccine that contained both the redesigned and original vaccines caused a 9.1- and 10.9-fold increase, they noted.
The results came from a trial with 1,234 people aged 56 and older. The vaccines were well tolerated by the participants, the companies said.
The companies noted that early laboratory studies suggest that both candidates modified by Omicron they neutralize the BA.4 and BA.5 subvariants that have been circulating more recently, although to a lesser extent than for BA.1, with approximately 3-fold lower titers.
The companies say they continue to collect data on the performance of the boosters against the strains that have circulated most recently.
modern inc. has also manufactured a redesigned vaccine targeting the BA.1 subvariant of Omicron. The company said its updated vaccine worked well against the latest Omicron subvariants, and it was moving forward with plans to apply for regulatory approval.